Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019210 | 0.89 | PGR (0.55) | PGRNR3C1NR3C2AREPHX2 | |
| SCHEMBL8052840 | 0.89 | PGR (0.55) | PGRNR3C1NR3C2AREPHX2 | |
| SCHEMBL3014377 | 0.88 | PGR (0.58) | PGRNR3C1NR3C2AREPHX2 | |
| SCHEMBL8066741 | 0.79 | PGR (0.53) | PGREPHX2PIK3CDHDAC1HDAC8 | |
| SCHEMBL3023025 | 0.78 | EPHX2 (0.53) | PGREPHX2PIK3CDHDAC1HDAC8 | |
| SCHEMBL12233708 | 0.78 | HDAC1 (0.52) | PGRNR3C1NR3C2AREPHX2 | |
| SCHEMBL3010046 | 0.77 | PGR (0.68) | PGREPHX2PIK3CDHDAC1HDAC8 | |
| SCHEMBL3016234 | 0.76 | PGR (0.77) | PGREPHX2PIK3CD | |
| SCHEMBL3020687 | 0.75 | PGR (0.76) | PGREPHX2PIK3CD | |
| SCHEMBL3009310 | 0.75 | PGR (0.48) | PGREPHX2PIK3CDHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | claimed |
| EP-2205079-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009045381-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | claimed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | disclosed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | disclosed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | PGR 4426/4885NR3C1 942/4885NR3C2 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.